Jim MIllen, Physiomics Plc's chief executive, explains how the trend towards personalised medicines will aid the commercialisation of its virtual tumour software.
UK development agency Innovate has given the group two grants to help with research in the area.
That follows deals with two large pharmaceutical companies and a biotech this year for the cancer modelling software.
Physiomics had already announced a ?,?500,000 contract with German group Merck Serono at the end of 2017.
Meet Peninsula Mines Ltd, Silver City Minerals Ltd and Emmerson Resources Ltd at our event,Sydney, 07 May 2018.Register here >>